• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MSB Mesoblast Presents At Credit Suisse Healthcare Conference09/11/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
MSB Ceasing to be a substantial holder30/10/17
MSB Ceasing to be a substantial holder27/10/17
MSB Becoming a substantial holder27/10/17
MSB Annual Report to shareholders16/10/17
MSB Notice of Annual General Meeting/Proxy Form16/10/17
MSB Appendix 4G and Corporate Governance Statement16/10/17
MSB Appendix 3B06/10/17
MSB End-Stage Heart Failure Trial Completes EnrollmentPRICE SENSITIVE28/09/17
MSB Mesoblast Corporate Updates at Healthcare ConferencesPRICE SENSITIVE25/09/17
MSB Change of Director's Interest Notices25/09/17
MSB Appendix 3B18/09/17
MSB Mesoblast Completes A$50.7 Million Raise15/09/17
MSB Change of Director Interest and Substantial Holding Notices06/09/17
MSB Change in substantial holding06/09/17
MSB Retail Entitlement OfferPRICE SENSITIVE01/09/17
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/17
MSB Annual Financial Results Presentation30/08/17
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/17
MSB Underwritten A$50.7M Raise Closes Institutional AllocationPRICE SENSITIVE29/08/17
MSB Cleansing notice25/08/17
MSB Appendix 3B25/08/17
MSB Fully Underwritten Entitlement Offer Presentation25/08/17
MSB Fully Underwritten A$50.7 Million Entitlement OfferPRICE SENSITIVE25/08/17
MSB Trading HaltPRICE SENSITIVE25/08/17
MSB Potential For Accelerated Market Entry In Advanced CHFPRICE SENSITIVE23/08/17
MSB Positive Results of MSB Therapy in Osteoarthritis PublishedPRICE SENSITIVE16/08/17
MSB Release of shares from voluntary escrow08/08/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
MSB Change in substantial holding13/07/17
MSB Cleansing notice and Appendix 3B10/07/17
MSB Mesoblast RA Results Presented At EULAR CongressPRICE SENSITIVE22/06/17
MSB MSB Provides Q3 Operational Highlights and Financial ResultsPRICE SENSITIVE25/05/17
MSB Third Quarter Results Presentation25/05/17
MSB Third Quarter Financial Results On Form 6-KPRICE SENSITIVE25/05/17
MSB Change of Director's Interest Notice02/05/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
MSB Change in substantial holding24/04/17
MSB Successful Interim Analysis in Phase 3 Heart Failure TrialPRICE SENSITIVE10/04/17
MSB Mesoblast Receives A$3.7m From Aus Govt For R&DPRICE SENSITIVE06/04/17
MSB FDA Clears Heart Disease Trial At Boston Childrens HospitalPRICE SENSITIVE04/04/17
MSB Change in substantial holding03/04/17
MSB Becoming a substantial holder from TEK31/03/17
MSB Cleansing notice and Appendix 3B31/03/17
MSB Process Initiated For CHF P3 Interim AnalysisPRICE SENSITIVE31/03/17
MSB Mesoblast Raises US$40 MillionPRICE SENSITIVE27/03/17
MSB Durable Three Year Outcomes in Disc DiseasePRICE SENSITIVE15/03/17
MSB FDA Grants Mesoblast Fast Track Designation For GVHDPRICE SENSITIVE07/03/17
MSB Mesoblast Provides Half Year Results And Corporate Update27/02/17
MSB Half Year Results Presentation27/02/17
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE27/02/17
MSB Presentation On Mesoblast RA P2 9 Month Trial Results16/02/17
MSB Positive Nine Month RA Results For Mesoblast Cell TherapyPRICE SENSITIVE16/02/17
MSB Published Results Show MSB Cells Effective In RA ModelPRICE SENSITIVE13/02/17
MSB Release of shares from voluntary escrow10/02/17
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
MSB Mesoblast Director Recognized For Cardiovascular LeadershipPRICE SENSITIVE31/01/17
MSB MSB Presentation To Annual J.P.Morgan Healthcare Conference13/01/17
MSB Presentation at JP Morgan Healthcare Conference11/01/17
MSB MSB Receives A$29.6Million, Appendix 3B Share Issue09/01/17
MSB Mesoblast And Mallinckrodt Enter Into AgreementPRICE SENSITIVE23/12/16
MSB New US Accelerated Approval Pathway For Cell Therapies09/12/16
MSB S&P DJ Indices Announces December Quarterly Rebalance09/12/16
MSB MD Anderson and NIH Fund Trial Using Mesoblast TechnologiesPRICE SENSITIVE06/12/16
MSB Results of Meeting22/11/16
MSB CEO Presentation to 2016 Annual General Meeting22/11/16
MSB Chairman's Address to Shareholders22/11/16
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/16
MSB First Quarter Results Presentation15/11/16
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/16
MSB Successful Interim Futility Analysis In P3 Trial for GVHDPRICE SENSITIVE14/11/16
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE31/10/16
MSB Annual Report to shareholders-MSB.AX 21/10/16
MSB Notice of Annual General Meeting/Proxy Form-MSB.AX 21/10/16
MSB Appendix 4G And Corporate Governance Statement-MSB.AX 21/10/16
MSB Mesoblast Receives Frost & Sullivan 2016 Cell Therapy Award-MSB.AX 18/10/16
MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX PRICE SENSITIVE12/10/16
MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX PRICE SENSITIVE06/10/16
MSB Mesoblast Appoints Bill Burns As Vice Chairman-MSB.AX 01/09/16
MSB Annual Financial Results Presentation-MSB.AX 28/08/16
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX PRICE SENSITIVE28/08/16
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX PRICE SENSITIVE28/08/16
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX PRICE SENSITIVE25/08/16
MSB Annual Financial Results Presentation-MSB.AX 25/08/16
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX PRICE SENSITIVE25/08/16
MSB Appendix 3B-MSB.AX 19/08/16
MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX PRICE SENSITIVE17/08/16
MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX PRICE SENSITIVE09/08/16
MSB Presentation On Mesoblast RA P2 Trial Results-MSB.AX 09/08/16
MSB MSB Back Pain Results Presented, Receive Best Science Award-MSB.AX PRICE SENSITIVE01/08/16
MSB Appendix 4C - quarterly-MSB.AX PRICE SENSITIVE29/07/16
MSB Update on Heart Failure Trial and Funding of Operations-MSB.AX PRICE SENSITIVE01/07/16
MSB Reinstatement to Official Quotation-MSB.AX PRICE SENSITIVE14/06/16
MSB Update on Global Heart Failure Program-MSB.AX PRICE SENSITIVE14/06/16
MSB Extension of Voluntary Suspension-MSB.AX 10/06/16
MSB Suspension from Official Quotation-MSB.AX PRICE SENSITIVE03/06/16
MSB Trading Halt-MSB.AX PRICE SENSITIVE01/06/16
MSB Mesoblast Receives $6.2m From Aus Govt For R&D-MSB.AX PRICE SENSITIVE20/05/16
MSB Ceasing to be a substantial holder-JP Morgan-MSB.AX 13/05/16
MSB Mesoblast Presents At Credit Suisse Healthcare Conference
09/11/17
MSB Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
MSB Ceasing to be a substantial holder
30/10/17
MSB Ceasing to be a substantial holder
27/10/17
MSB Becoming a substantial holder
27/10/17
MSB Annual Report to shareholders
16/10/17
MSB Notice of Annual General Meeting/Proxy Form
16/10/17
MSB Appendix 4G and Corporate Governance Statement
16/10/17
MSB Appendix 3B
06/10/17
MSB End-Stage Heart Failure Trial Completes Enrollment
28/09/17PRICE SENSITIVE
MSB Mesoblast Corporate Updates at Healthcare Conferences
25/09/17PRICE SENSITIVE
MSB Change of Director's Interest Notices
25/09/17
MSB Appendix 3B
18/09/17
MSB Mesoblast Completes A$50.7 Million Raise
15/09/17
MSB Change of Director Interest and Substantial Holding Notices
06/09/17
MSB Change in substantial holding
06/09/17
MSB Retail Entitlement Offer
01/09/17PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/17PRICE SENSITIVE
MSB Annual Financial Results Presentation
30/08/17
MSB Preliminary Final Report including Appendix 4E
30/08/17PRICE SENSITIVE
MSB Underwritten A$50.7M Raise Closes Institutional Allocation
29/08/17PRICE SENSITIVE
MSB Cleansing notice
25/08/17
MSB Appendix 3B
25/08/17
MSB Fully Underwritten Entitlement Offer Presentation
25/08/17
MSB Fully Underwritten A$50.7 Million Entitlement Offer
25/08/17PRICE SENSITIVE
MSB Trading Halt
25/08/17PRICE SENSITIVE
MSB Potential For Accelerated Market Entry In Advanced CHF
23/08/17PRICE SENSITIVE
MSB Positive Results of MSB Therapy in Osteoarthritis Published
16/08/17PRICE SENSITIVE
MSB Release of shares from voluntary escrow
08/08/17
MSB Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
MSB Change in substantial holding
13/07/17
MSB Cleansing notice and Appendix 3B
10/07/17
MSB Mesoblast RA Results Presented At EULAR Congress
22/06/17PRICE SENSITIVE
MSB MSB Provides Q3 Operational Highlights and Financial Results
25/05/17PRICE SENSITIVE
MSB Third Quarter Results Presentation
25/05/17
MSB Third Quarter Financial Results On Form 6-K
25/05/17PRICE SENSITIVE
MSB Change of Director's Interest Notice
02/05/17
MSB Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
MSB Change in substantial holding
24/04/17
MSB Successful Interim Analysis in Phase 3 Heart Failure Trial
10/04/17PRICE SENSITIVE
MSB Mesoblast Receives A$3.7m From Aus Govt For R&D
06/04/17PRICE SENSITIVE
MSB FDA Clears Heart Disease Trial At Boston Childrens Hospital
04/04/17PRICE SENSITIVE
MSB Change in substantial holding
03/04/17
MSB Becoming a substantial holder from TEK
31/03/17
MSB Cleansing notice and Appendix 3B
31/03/17
MSB Process Initiated For CHF P3 Interim Analysis
31/03/17PRICE SENSITIVE
MSB Mesoblast Raises US$40 Million
27/03/17PRICE SENSITIVE
MSB Durable Three Year Outcomes in Disc Disease
15/03/17PRICE SENSITIVE
MSB FDA Grants Mesoblast Fast Track Designation For GVHD
07/03/17PRICE SENSITIVE
MSB Mesoblast Provides Half Year Results And Corporate Update
27/02/17
MSB Half Year Results Presentation
27/02/17
MSB Half Year Report and Accounts (including Appendix 4D)
27/02/17PRICE SENSITIVE
MSB Presentation On Mesoblast RA P2 9 Month Trial Results
16/02/17
MSB Positive Nine Month RA Results For Mesoblast Cell Therapy
16/02/17PRICE SENSITIVE
MSB Published Results Show MSB Cells Effective In RA Model
13/02/17PRICE SENSITIVE
MSB Release of shares from voluntary escrow
10/02/17
MSB Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
MSB Mesoblast Director Recognized For Cardiovascular Leadership
31/01/17PRICE SENSITIVE
MSB MSB Presentation To Annual J.P.Morgan Healthcare Conference
13/01/17
MSB Presentation at JP Morgan Healthcare Conference
11/01/17
MSB MSB Receives A$29.6Million, Appendix 3B Share Issue
09/01/17
MSB Mesoblast And Mallinckrodt Enter Into Agreement
23/12/16PRICE SENSITIVE
MSB New US Accelerated Approval Pathway For Cell Therapies
09/12/16
MSB S&P DJ Indices Announces December Quarterly Rebalance
09/12/16
MSB MD Anderson and NIH Fund Trial Using Mesoblast Technologies
06/12/16PRICE SENSITIVE
MSB Results of Meeting
22/11/16
MSB CEO Presentation to 2016 Annual General Meeting
22/11/16
MSB Chairman's Address to Shareholders
22/11/16
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/16PRICE SENSITIVE
MSB First Quarter Results Presentation
15/11/16
MSB First Quarter Results On Form 6K
15/11/16PRICE SENSITIVE
MSB Successful Interim Futility Analysis In P3 Trial for GVHD
14/11/16PRICE SENSITIVE
MSB Appendix 4C - quarterly-MSB.AX
31/10/16PRICE SENSITIVE
MSB Annual Report to shareholders-MSB.AX
21/10/16
MSB Notice of Annual General Meeting/Proxy Form-MSB.AX
21/10/16
MSB Appendix 4G And Corporate Governance Statement-MSB.AX
21/10/16
MSB Mesoblast Receives Frost & Sullivan 2016 Cell Therapy Award-MSB.AX
18/10/16
MSB MSB Japan Strategy Highlighted At Business Council Meeting-MSB.AX
12/10/16PRICE SENSITIVE
MSB Mesoblast Phase 2 Diabetic Kidney Disease Results Published-MSB.AX
06/10/16PRICE SENSITIVE
MSB Mesoblast Appoints Bill Burns As Vice Chairman-MSB.AX
01/09/16
MSB Annual Financial Results Presentation-MSB.AX
28/08/16
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX
28/08/16PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX
28/08/16PRICE SENSITIVE
MSB Mesoblast Reports on Annual and Fourth Quarter Results-MSB.AX
25/08/16PRICE SENSITIVE
MSB Annual Financial Results Presentation-MSB.AX
25/08/16
MSB Preliminary Final Report (Including Appendix 4E)-MSB.AX
25/08/16PRICE SENSITIVE
MSB Appendix 3B-MSB.AX
19/08/16
MSB MSB Strengthens US Patent Portfolio For Rheumatic Diseases-MSB.AX
17/08/16PRICE SENSITIVE
MSB Mesoblast P2 Results Show Dose-Related Improvements In RA-MSB.AX
09/08/16PRICE SENSITIVE
MSB Presentation On Mesoblast RA P2 Trial Results-MSB.AX
09/08/16
MSB MSB Back Pain Results Presented, Receive Best Science Award-MSB.AX
01/08/16PRICE SENSITIVE
MSB Appendix 4C - quarterly-MSB.AX
29/07/16PRICE SENSITIVE
MSB Update on Heart Failure Trial and Funding of Operations-MSB.AX
01/07/16PRICE SENSITIVE
MSB Reinstatement to Official Quotation-MSB.AX
14/06/16PRICE SENSITIVE
MSB Update on Global Heart Failure Program-MSB.AX
14/06/16PRICE SENSITIVE
MSB Extension of Voluntary Suspension-MSB.AX
10/06/16
MSB Suspension from Official Quotation-MSB.AX
03/06/16PRICE SENSITIVE
MSB Trading Halt-MSB.AX
01/06/16PRICE SENSITIVE
MSB Mesoblast Receives $6.2m From Aus Govt For R&D-MSB.AX
20/05/16PRICE SENSITIVE
MSB Ceasing to be a substantial holder-JP Morgan-MSB.AX
13/05/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.